These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11167667)

  • 1. Population modelling of the effect of inogatran, at thrombin inhibitor, on ex vivo coagulation time (APTT) in healthy subjects and patients with coronary artery disease.
    Cullberg M; Eriksson UG; Larsson M; Karlsson MO
    Br J Clin Pharmacol; 2001 Jan; 51(1):71-9. PubMed ID: 11167667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease.
    Oldgren J; Linder R; Grip L; Siegbahn A; Wallentin L
    Eur Heart J; 1999 Nov; 20(22):1657-66. PubMed ID: 10543929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group.
    Eur Heart J; 1997 Sep; 18(9):1416-25. PubMed ID: 9458447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease.
    Linder R; Oldgren J; Egberg N; Grip L; Larson G; Siegbahn A; Wallentin L
    Eur Heart J; 1999 Apr; 20(7):506-18. PubMed ID: 10365287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombin inhibition with inogatran for unstable angina pectoris: evidence for reactivated ischaemia after cessation of short-term treatment.
    Andersen K; Dellborg M; Emanuelsson H; Grip L; Swedberg K
    Coron Artery Dis; 1996 Sep; 7(9):673-81. PubMed ID: 8950498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-effect relationship for several coagulation markers during administration of the direct thrombin inhibitor S 18326 in healthy subjects.
    Gaussem P; Dubar M; le Bonniec B; Richard-Lordereau I; Jochemsen R; Aiach M
    Br J Clin Pharmacol; 2002 Feb; 53(2):147-54. PubMed ID: 11851638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
    Chen LY; Nichols WW; Mattsson C; Teger-Nilson AC; Wallin R; Saldeen TG; Mehta JL
    Cardiovasc Res; 1995 Dec; 30(6):866-74. PubMed ID: 8746200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis.
    Liesenfeld KH; Schäfer HG; Trocóniz IF; Tillmann C; Eriksson BI; Stangier J
    Br J Clin Pharmacol; 2006 Nov; 62(5):527-37. PubMed ID: 17061960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples.
    Hapgood G; Butler J; Malan E; Chunilal S; Tran H
    Thromb Haemost; 2013 Aug; 110(2):308-15. PubMed ID: 23783268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis.
    Chen L; Nichols WW; Mattsson C; Teger-Nilsson AC; Saldeen TG; Mehta JL
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1276-83. PubMed ID: 8667188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran.
    Eriksson UG; Johansson S; Attman PO; Mulec H; Frison L; Fager G; Samuelsson O
    Clin Pharmacokinet; 2003; 42(8):743-53. PubMed ID: 12846595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
    Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD
    Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
    Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
    Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
    Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
    Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin resistance in acute coronary syndromes.
    Rich JD; Maraganore JM; Young E; Lidon RM; Adelman B; Bourdon P; Charenkavanich S; Hirsh J; Theroux P; Cannon CP
    J Thromb Thrombolysis; 2007 Apr; 23(2):93-100. PubMed ID: 17221324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
    Lindahl TL; Baghaei F; Blixter IF; Gustafsson KM; Stigendal L; Sten-Linder M; Strandberg K; Hillarp A;
    Thromb Haemost; 2011 Feb; 105(2):371-8. PubMed ID: 21103660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crossover dose escalation study to assess safety, pharmacokinetics, and pharmacodynamics of single doses of R1663, an oral factor Xa inhibitor, in healthy male volunteers.
    Schmitt C; Pannier A; McIntyre C; Zandt H; Ciorciaro C; Winters K; Pepper T
    J Clin Pharmacol; 2012 Apr; 52(4):499-510. PubMed ID: 21566199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.
    Elg M; Gustafsson D; Deinum J
    Thromb Haemost; 1997 Oct; 78(4):1286-92. PubMed ID: 9364999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro effects of inogatran, a selective low molecular weight thrombin inhibitor.
    Teger-Nilsson AC; Bylund R; Gustafsson D; Gyzander E; Eriksson U
    Thromb Res; 1997 Jan; 85(2):133-45. PubMed ID: 9058487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombotic activity of inogatran, a new low-molecular-weight inhibitor of thrombin, in a closed-chest porcine model of coronary artery thrombosis.
    Uriuda Y; Wang QD; Grip L; Rydén L; Sjöquist PO; Mattsson C
    Cardiovasc Res; 1996 Aug; 32(2):320-7. PubMed ID: 8796119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.